Sorrento Therapeutics (SRNE)

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.

Company profile

Henry Ji
Fiscal year end
Former names
Concortis Biosystems, Corp. • Ark Animal Health, Inc. • TNK Therapeutics, Inc. • BioServ Corporation • Adnab, Inc. • ACEA Therapeutics, Inc. • Scilex Holding Company • Semnur Pharmaceuticals, Inc. • Scilex Pharmaceuticals Inc. • Levena Biopharma US, Inc. ...
IRS number

SRNE stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


4 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 111.91M 111.91M 111.91M 111.91M 111.91M 111.91M
Cash burn (monthly) (no burn) (no burn) 35.63M 47.68M 27.79M 26.43M
Cash used (since last report) n/a n/a 157.28M 210.49M 122.66M 116.66M
Cash remaining n/a n/a -45.37M -98.58M -10.76M -4.75M
Runway (months of cash) n/a n/a -1.3 -2.1 -0.4 -0.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Jun 22 Ji Henry Common Stock Buy Acquire P No No 1.3999 10,000 14K 2,065,807
18 May 22 Tammy Reilly Stock Option Common Stock Grant Acquire A No No 1.51 100,000 151K 100,000
18 May 22 Czerepak Elizabeth Stock Option Common Stock Grant Acquire A No No 1.51 350,000 528.5K 350,000
27 Dec 21 Janda Kim Common Stock Sell Dispose S No Yes 5.88 3,000 17.64K 3,000
27 Dec 21 Janda Kim Common Stock Option exercise Acquire M No Yes 4 3,000 12K 6,000
27 Dec 21 Janda Kim NQSO Common Stock Option exercise Dispose M No Yes 4 3,000 12K 0
39.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 232 233 -0.4%
Opened positions 41 51 -19.6%
Closed positions 42 39 +7.7%
Increased positions 83 69 +20.3%
Reduced positions 35 57 -38.6%
13F shares Current Prev Q Change
Total value 579.76M 592.49M -2.1%
Total shares 153.48M 118.68M +29.3%
Total puts 1.41M 2.04M -30.9%
Total calls 2.75M 4.1M -32.9%
Total put/call ratio 0.5 0.5 +3.1%
Largest owners Shares Value Change
STT State Street 33.96M $79.13M +132.7%
BLK Blackrock 22.03M $51.34M +1.2%
Vanguard 15.9M $37.05M +1.3%
D. E. Shaw & Co. 7.24M $16.87M +195.9%
Famous Sino 5.96M $40.71M 0.0%
Geode Capital Management 4.99M $11.62M -5.9%
China In Shine Investment 4.76M $32.49M 0.0%
Ally Bridge Group Capital Partners II 4.45M $12.1M 0.0%
Hongguo International 4.07M $27.81M 0.0%
Asia Pacific MedTech 3.55M $24.22M 0.0%
Largest transactions Shares Bought/sold Change
STT State Street 33.96M +19.37M +132.7%
D. E. Shaw & Co. 7.24M +4.79M +195.9%
MS Morgan Stanley 3.28M +2.37M +259.2%
Sabby Management 0 -2.19M EXIT
Marshall Wace 1.66M +1.66M NEW
UBS UBS Group AG - Registered Shares 2.48M +1.63M +192.2%
Rafferty Asset Management 2.47M +1.62M +190.5%
Susquehanna International 2.13M +1.38M +182.4%
Two Sigma Investments 1.09M +1.09M NEW
BAC Bank Of America 1.29M +1.08M +496.1%

Content analysis

H.S. sophomore Avg
New words: AB, advocacy, affordable, African, agnostic, Alaska, appealed, Asian, assay, ATM, avoid, bankruptcy, bear, benchmark, Bill, bioavailability, Biopharma, Bioserv, bisexual, Black, Boston, bridge, bring, bringing, Cantor, capability, climate, complex, compliance, comply, condensed, consummated, COVIMARK, criminal, decided, deficiency, deficient, delisting, desensitization, deteriorate, devote, director, enacted, environmental, ESG, female, fine, Fitzgerald, found, framework, franchise, frequently, FUJOVEE, gay, gender, glucose, guide, Hawaiian, headquartered, Hispanic, inaccuracy, inadequate, insolvency, institutional, Islander, Latino, leave, lesbian, Levena, listed, listing, mentioned, merit, mesynstromal, misstatement, Native, notice, OQORY, Pacific, passed, passing, pathogen, peripherally, pertaining, pill, precluded, predetermined, prescribed, prescription, prevail, pro, proposed, protease, quota, rata, recoverable, relevant, reliability, reliable, remedial, remediate, remediated, remediation, reputation, reputational, Riley, satisfy, SB, scalable, SCLX, SCLXW, scrutinizing, Secretary, Senator, settled, stipulated, strip, summarize, sustainability, sustained, tangible, threshold, timeline, transgender, unclear, unconstitutional, underrepresented, Vantage, variant, VCKA, VCKAU, VCKAW, virex, Wainwright, waiver
Removed: ablate, acceleration, accredited, accuracy, achieved, acquiring, acute, adenocarcinoma, adequate, adequately, administration, adnab, advanced, advantage, affecting, affinity, aim, allogeneic, altered, altogether, amalgamation, amending, Amendment, amplification, amyloid, ANVISA, application, approach, approve, approving, area, arrangement, ASC, ascending, assembled, attempt, audited, authorization, autoimmune, automatic, awaiting, began, begin, beginning, beneficial, bifurcation, biomarker, bispecific, branded, Brazilian, Broadly, Bruton, BTK, building, carcinoembryonic, care, carry, cease, cell, cellular, chain, chance, checkpoint, chimeric, choice, clarifying, classified, cleared, clinic, clinically, close, cocktail, collaborative, colloid, colorectal, colorimetric, Columbia, commenced, commercially, commitment, competing, confounding, Consent, constantly, construct, consumed, continuum, core, cover, covering, COVIDROPSTM, COVIGUARD, COVIGUARDTM, COVISHIELDTM, COVITRACE, COVITRACKTM, create, cytokine, data, decreased, deductible, deep, defunctionalize, delivering, depend, depending, description, design, destroy, developed, dexamethasone, difficult, digit, dilutive, dimeric, directly, disruption, distancing, distribution, diversification, DNA, dose, dosed, dual, durable, duration, earliest, ease, economically, efficacy, eleven, elimination, embedded, emergency, emerging, end, endpoint, engineered, engineering, enhanced, enhancement, enhancing, enrolled, enrolling, enrollment, entering, entitled, entry, equilibrium, escape, established, EUA, Europe, evolution, evolving, execution, exemption, exit, explanatory, exploit, expressing, extend, extension, facilitating, factor, fail, fee, fighting, finalization, finance, firm, flexibility, Food, force, formulated, gene, generate, genetic, genomic, global, globally, goal, half, healthcare, healthy, heightened, high, hire, hospitalized, Ib, IBRX, Icahn, immune, ImmunityBio, impacted, implementing, imposing, improved, inability, incurrence, IND, indemnification, inflammatory, influence, influenza, initial, initially, initiated, injection, injury, innovative, instability, instrument, intact, intense, intermediate, internally, international, intranasal, intrathecal, Investigational, irrevocable, isolate, kinase, kit, largely, leading, lengthy, leveraged, licensed, life, limiting, liquid, liquidated, lived, long, lumbosacral, mab, making, matured, maximize, Mayo, meaningful, Medicine, mesenchymal, met, mg, mild, milestone, misinterpret, mission, mitigate, molecule, monoclonal, Mount, multimodal, multipronged, myeloma, NantKwest, nerve, neuralgia, neurodegenerative, neuropathic, notwithstanding, Oaktree, objective, obtained, obtaining, offer, offset, operational, optimize, optimized, optional, oral, orphan, outbreak, outcome, outpatient, outweigh, palliative, pancreatic, paragraph, parenteral, partial, partnering, people, phosphate, planned, point, portfolio, post, postherpetic, predictive, prepayment, prevention, primary, proactive, procedure, profitability, profitable, progressed, promising, prosecuting, protein, put, quality, quickly, radicular, rare, receive, redemption, reduce, reducing, reflective, refractory, refuse, registered, registration, Regulation, relapsed, release, released, reliance, relinquish, remain, remote, removing, representation, representative, repurchase, resale, reserve, resistant, respiratory, responsible, responsibly, restrictive, restructuring, return, revoke, risky, RNA, robust, royalty, RRMM, saliva, sample, School, sciatica, scientific, screening, scrutiny, security, select, selected, Semnur, sensitivity, SeprehvecTM, serological, shallow, sheet, show, shown, signaling, signature, simple, simplify, Simplifying, Sinai, site, situation, small, sodium, solid, speaking, speculative, spending, spread, staffing, standby, statement, step, steroid, storm, strength, study, studying, sublicensable, sublicense, submitted, successfully, suffer, suffering, suitable, supported, survival, swab, syndrome, system, systemic, tailor, targeting, technological, technology, temporarily, term, terminated, termination, therapy, thereon, throughput, timing, TM, today, tolerance, toxin, traded, train, trauma, treat, treated, treating, treatment, tyrosine, uncertain, uncertainty, uncommon, underlying, underserved, University, unmet, unresectable, unsuccessful, utilized, utilizing, view, viral, vision, warrant, wholly, wide, widespread, wind, workforce, world